Wall Street is taking Abbott's claim that it is not interested in St. Jude Medical at face value, paving the way for speculation about who the drug and devicemaker will buy instead as it seeks to deploy plentiful cash and bulk up in med tech following a wave of industry M&A.
News that Abbott is preparing a $25 billion bid for drugmaker St. Jude Medical hogged the headlines this morning, but in the latest twist, the drug and devicemaker just told Reuters it is not interested in St. Jude.
A survey conducted by Abbott concludes that most adults do not recognize common concussion symptoms.
U.S.-based Abbott Laboratories is among a number of companies that hope to leverage acquisitions in Russia into exports, with other players such as India's Lupin among other potential firms to look to ship wider abroad.
Abbott will buy two mitral valve replacement startups, moving it even further into med tech after a series of high-profile deals last year. It obviously sees the sector as a way for it to plan for long-term growth--since its innovative biopharma candidates went with AbbVie when the companies split in early 2013.
Mylan can breathe a little easier knowing it has support from its largest shareholder in its quest to pick up Perrigo. After all, it's not just a big buyout at stake--but the opportunity to thwart its own unwanted takeover by generics rival Teva.
Abbott just announced the CE marking of its latest Absorb bioresorbable stent at the annual EuroPCR conference in Paris. The device is called the Absorb GT1, in reference to its GlideTrak delivery catheter, which is supposed to make it easier for doctors to access and treat diseased vessels among coronary artery disease patients.
A study presented at the annual Heart Rhythm Society meeting in Boston found that Abbott's percutaneous MitraClip mitral valve repair device cut the number of ventricular tachyarrhythmia episodes in half following implantation in patients who had a prior cardiac rhythm device like a pacemaker or implantable cardioverter defibrillator.
Last year, Mylan forked over millions to cover its top execs' tax liability on its deal with Abbott Laboratories, which shifted its tax domicile to Europe. Investors weren't so lucky--and now, they may take another tax hit if Mylan joins up with suitor Teva.
Abbott and GE Healthcare are teaming up for a diagnostics collaboration aimed at improving treatment for patients with atrial fibrillation, planning to combine the companies' innovative technology to speed up diagnosis for individuals with heart rhythm disorders.